CJC-1295 is a synthetic analogue of growth hormone releasing hormone (GHRH) designed with increased half-life through drug affinity complex (DAC) technology. In research settings it is studied for its effects on growth hormone secretion and downstream IGF-1 signaling. It is frequently paired with ipamorelin in research protocols examining GH pulse amplitude and frequency.
CJC-1295 with and without DAC
CJC-1295 comes in two variants: with DAC (Drug Affinity Complex) and without DAC (also called Mod GRF 1-29). The DAC version has a significantly longer half-life due to its ability to bind albumin. The no-DAC version has a shorter activity window more closely mimicking natural GHRH pulses. Most research protocols specify which version they require — they are not interchangeable, and vendors should clearly label which form they supply.
CJC-1295 + Ipamorelin stack
CJC-1295 is almost universally studied in combination with ipamorelin in research models. CJC-1295 stimulates GHRH receptor signaling to increase GH pulse amplitude, while ipamorelin acts as a ghrelin mimetic to stimulate GH release through a distinct receptor pathway. Together they provide a synergistic model for studying GH secretion without significant cortisol or prolactin effects observed in older secretagogue research.
Verification requirements
CJC-1295 should be verified with HPLC (≥98% purity) and mass spec. Critically, the COA must specify whether the product contains the DAC modification or not, as in-house mislabeling between the two variants is a documented quality control failure in lower-tier vendors. Always verify the molecular weight in the MS data: CJC-1295 with DAC has a MW of approximately 3647 Da; without DAC (Mod GRF 1-29) is approximately 3368 Da.
See all CJC-1295 vendors ranked
PeptideComparison independently scores every vendor on COA quality (weighted 2×), price, reviews, shipping, and availability. Click below to see the full ranked list filtered to CJC-1295 vendors.
View CJC-1295 vendor rankings →